psoriasis

Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial
Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial
BioSpace
Sienna Biopharmaceuticals
bankruptcy
psoriasis
SNA-120
Flag link:
Skyrizi looks ready to soar after strong launch
Skyrizi looks ready to soar after strong launch
Biopharma Dive
AbbVie
Skyrizi
psoriasis
Flag link:
Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger
Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger
Stat
Amgen
Otezla
Celgene
M&A
Bristol-Myers Squibb
psoriasis
Flag link:
5 Biggest New Drugs Approved in 2019 So Far
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Flag link:
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Fierce Pharma
Eli Lilly
Taltz
JNJ
Tremfya
psoriasis
Flag link:
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
Fierce Pharma
AbbVie
Humira
biosimilars
Europe
psoriasis
rheumatoid arthritis
Skyrizi
Flag link:
Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales
Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales
Fierce Pharma
Eli Lilly
Taltz
psoriasis
Flag link:
Ramaswamy's Dermavant Updates $124 Million IPO Filing
Ramaswamy's Dermavant Updates $124 Million IPO Filing
CP Wire
Dermavant
IPOs
tapinarof
psoriasis
dermatitis
Vivek Ramaswamy
Flag link:
Ramaswamy's Dermavant Updates $124 Million IPO Filing
Dermavant
tapinarof
psoriasis
dermatitis
IPOs
Flag link:
AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst
AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst
Fierce Pharma
AbbVie
Humira
Skyrizi
drug launches
psoriasis
drug pricing
formulary
Flag link:
AbbVie successor to Humira in psoriasis gains FDA approval
AbbVie successor to Humira in psoriasis gains FDA approval
BioCentury
AbbVie
Humira
psoriasis
Skyrizi
FDA
Flag link:
AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales
AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales
Endpoints
AbbVie
Japan
psoriasis
risankizumab
Skyrizi
Flag link:
AbbVie's immunology blockbuster-to-be Skyrizi picks up first global approval
AbbVie's immunology blockbuster-to-be Skyrizi picks up first global approval
Fierce Pharma
AbbVie
Japan
Skyrizi
psoriasis
psoriatic arthritis
Flag link:
4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Pharmaceutical Business Review
Novartis
Cosentyx
China
psoriasis
Flag link:
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
RAPS.org
Novartis
Janssen
JNJ
psoriasis
false advertising
Tremfya
Flag link:
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Fierce Pharma
JNJ
Janssen
Tremfya
psoriasis
Novartis
Cosentyx
Eli Lilly
Taltz
Flag link:
FDA approves J&J’s Tremfya self-injection pen for psoriasis
FDA approves J&J’s Tremfya self-injection pen for psoriasis
Drug Delivery Business News
JNJ
FDA
Tremfya
psoriasis
Flag link:
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
Fierce Pharma
JNJ
JPMHC 2019
immunology
psoriasis
Tremfya
Flag link:
Microbiome Report for Week Ending 12/1/18
Microbiome Report for Week Ending 12/1/18
CP Wire
microbiome
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:

Pages